What Kratom Is, and Why It Reaches This Audience

Kratom comes from the leaves of Mitragyna speciosa, a tree native to Southeast Asia. Its principal active alkaloids are mitragynine and 7-hydroxymitragynine (7-OH), and both act on opioid receptors. That is the core fact to hold on to: whatever it is sold as, its pharmacology is opioid-like. It is typically sold as a powder, capsule, extract, gummy or drink, and marketed for energy at low doses and pain relief or sedation at higher ones.

The reason it turns up in a GLP-1 context is straightforward. The most common early side effects of GLP-1 titration are nausea, fatigue and low energy, and kratom is marketed at precisely those complaints. It is also sold in the supplement aisle rather than the pharmacy, which makes it read as lower-stakes than the pharmacology warrants.

What the FDA Actually Documents

This is not a matter of opinion or of general caution about supplements. The FDA states that published scientific literature and adverse event reports on kratom and kratom-derived products raise safety concerns including:

• ▪Liver toxicity
• ▪Cardiovascular toxicity
• ▪Seizures
• ▪Gastrointestinal distress
• ▪Respiratory depression
• ▪Addiction and withdrawal symptoms
• ▪Death

Kratom alkaloids have been detected in overdose deaths, frequently in combination with other substances — which is relevant precisely because the readers of this page are, by definition, taking something else.

The 7-OH enforcement timeline

Regulatory attention has concentrated on concentrated 7-OH products rather than the leaf itself, and it has moved quickly:

• ▪July 2025 — the FDA issued warning letters to seven companies marketing and distributing illegal 7-OH products, including tablets, gummies, drink mixes and liquid shots.
• ▪December 2025 — the FDA, with the Department of Justice and US Marshals Service, seized approximately $1 million of unlawful 7-OH dietary supplement and food products from three firms in Missouri.
• ▪1 July 2026 — the DEA announced the start of temporary scheduling under the Controlled Substances Act for 7-OH above a proposed threshold, together with three synthetic 7-OH derivatives that do not occur naturally in the plant.

The scheduling action is not intended to capture the botanical leaf. But the direction of travel is unambiguous, and 7-OH is the alkaloid most responsible for opioid-receptor binding and abuse potential.

Why the Combination Specifically Matters

1. Both slow your gut

GLP-1 medications delay gastric emptying — that is part of how they work, it appears in the FDA labelling, and ileus was added to the Ozempic label as a post-marketing adverse event in September 2023. Constipation is already among the most frequently reported GLP-1 side effects.

Slowed gut transit and constipation are likewise a well-established consequence of opioid-receptor agonism, which is what kratom's alkaloids do. Stacking two things that slow the gastrointestinal tract, when one of them already lists ileus as a reported adverse event, is the clearest reason to keep these apart.

2. Kratom interferes with how other drugs are metabolised

Mitragynine causes time-dependent inhibition of CYP3A and acts as a strong competitive inhibitor of CYP2D6 — two enzymes responsible for metabolising a very large share of common prescription medicines, including many antidepressants, statins, beta blockers and benzodiazepines. In clinical study, a 2g kratom dose produced a modest increase in exposure to midazolam, a CYP3A probe drug, and mechanistic modelling predicted a substantially larger effect. Researchers have specifically noted that taking kratom alongside drugs metabolised by CYP2D6 and CYP3A4 could raise the risk of serious adverse effects.

Most people on a GLP-1 take other medications. That is the population in which this interaction matters most.

3. Surgery and sedation

GLP-1 medications already complicate anesthesia. FDA labelling notes rare post-marketing reports of pulmonary aspiration in patients undergoing procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to fasting instructions, and multi-society guidance issued in 2024 asks for risk stratification and coordination with anesthesia providers rather than routine drug holds. Adding a second agent that slows gastric emptying is information your anesthesia team needs.

If You Already Use Kratom

Nothing here is intended to alarm someone already using it, and abrupt cessation is not automatically the right move — withdrawal is one of the documented effects.

• ▪Tell your prescriber. Not as a confession — as information they need to manage your treatment safely. It is relevant to your constipation, your other prescriptions and any procedure you may have.
• ▪Take constipation seriously. On a GLP-1, this is the symptom most likely to be compounded. Severe or persistent constipation, especially with abdominal pain, distension or vomiting, warrants prompt medical attention rather than more fibre.
• ▪Do not stop abruptly without advice if you have been using it regularly. Withdrawal is documented, and a clinician can help you plan it.
• ▪Be specific about the product. Concentrated 7-OH extracts are pharmacologically different from plain leaf, and are the subject of the enforcement above.

Better Answers to the Problems It Is Sold For

If nausea, constipation or fatigue on a GLP-1 is what sent you looking, those have real management strategies that do not involve an opioid-receptor agonist. Dose titration pace is the biggest lever and is entirely in your prescriber's hands — and a provider that answers messages promptly matters here more than most people expect, which is why we cover support quality across providers. Our side effects guide covers the practical measures, and protein and fibre do more for gut symptoms than any supplement marketed at them.

Frequently Asked Questions

Where to Go Next

• ▪GLP-1 side effects guide — what to expect and how to manage it properly
• ▪When to talk to a doctor about supplements — which combinations warrant a conversation
• ▪“Ozempic alternative” supplement claims — how this category markets itself